News and updates covered here include a questionable justification for the sale of two fast-growing companies by an AIM listed group. Elsewhere, there were significant contract wins for others and a hefty funds raise for one popular company. Read on here for more on this and other news.
hVIVO: another contract - it’s all about the execution
hVIVO (AIM: HVO), a specialist contract research organisation (CRO) and apparent “world leader” in testing infectious and respiratory disease products using human challenge clinical trials, announced a £6.8m contract with a leading pharmaceutical company based in Asia Pacific.
The contract covers the testing of its respiratory syncytial virus ("RSV") antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model and will take…
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.
